RCAN1 and neoplasm: By cloning the RCAN1-422-32-reactive T cell receptor (TCR) derived from single-cell sequencing, we constructed RCAN1-422-32-specific TCR-engineered T cells (TCR-T cells) and validated their efficacy in killing tumor cells in vitro and reducing the tumor burden in vivo.